|
Daisies lead scientists down path to new leukemia drug
October 03, 2007Rochester team develops compound to attack cancer stem cells
A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.
The Rochester team has been leading the investigation of this promising therapy on the deadly blood cancer for nearly five years. And to bring it from a laboratory concept to patient studies in that time is very fast progress in the drug development world, said Craig T. Jordan, Ph.D., senior author of the Blood article and director of Translational Research for Hematologic Malignancies at the James P. Wilmot Cancer Center, at the University of Rochester Medical Center.
Clinical trials are expected to begin in England by the end of 2007. Investigators expect to initially enroll about a dozen adult volunteers who've been diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or other types of blood or lymph cancers, Jordan said.
Under development is dimethylamino-parthenolide (DMAPT), a form of parthenolide (PTL) that is derived from a daisy-like plant known as feverfew or bachelor's button. DMAPT is a water-soluble agent that scientists believe will selectively target leukemia at the stem-cell level, where the malignancy is born. This is significant because standard chemotherapy does not strike deep enough to kill cancer at the roots, thus resulting in relapses. Even the most progressive new therapies, such as Gleevec, are effective only to a degree because they do not reach the root of the cancer.
DMAPT appears to be unique. It's mechanism of action is to boost the cancer cell's reactive oxygen species - which is like pushing the stress level of the cell over the edge - to the point where the cell can no long protect itself and dies, said Monica L. Guzman, Ph.D., the lead researcher on the DMAPT project and a senior instructor at the University of Rochester Medical Center.
Leukemia is different from most cancers and particularly hard to eradicate because leukemia stem cells lie dormant. Standard cancer treatments are designed to seek out actively dividing cells. But in studies so far, DMAPT can kill both dormant cells and cells that are busy dividing, Guzman said
Rochester investigators looked at whether DMAPT could eliminate leukemia in donated human cells, and in mice and dogs. In all cases, DMAPT induced rapid death of AML stem and progenitor cells, without harming healthy blood cells.
DMAPT also has shown potential as a treatment for breast and prostate cancer, melanoma, and multiple myeloma, Guzman said, although those studies have only been conducted in cell cultures to date.
"Once we begin seeing evidence from the clinical trials, it will give us more insight into the pharmacological properties of DMAPT and it will be easier to figure out its potential for other cancers," Guzman said.
In addition to the studies of DMAPT, Guzman and Jordan also reported in the same issue of Blood on another new type of leukemia drug known as TDZD-8. Although this agent is at a much earlier stage of development, it also shows the ability to kill leukemia stem cells and may some day lead to better forms of treatment.
University of Rochester Medical Center
Clinical trials are expected to begin in England by the end of 2007. Investigators expect to initially enroll about a dozen adult volunteers who've been diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or other types of blood or lymph cancers, Jordan said.
Under development is dimethylamino-parthenolide (DMAPT), a form of parthenolide (PTL) that is derived from a daisy-like plant known as feverfew or bachelor's button. DMAPT is a water-soluble agent that scientists believe will selectively target leukemia at the stem-cell level, where the malignancy is born. This is significant because standard chemotherapy does not strike deep enough to kill cancer at the roots, thus resulting in relapses. Even the most progressive new therapies, such as Gleevec, are effective only to a degree because they do not reach the root of the cancer.
DMAPT appears to be unique. It's mechanism of action is to boost the cancer cell's reactive oxygen species - which is like pushing the stress level of the cell over the edge - to the point where the cell can no long protect itself and dies, said Monica L. Guzman, Ph.D., the lead researcher on the DMAPT project and a senior instructor at the University of Rochester Medical Center.
Leukemia is different from most cancers and particularly hard to eradicate because leukemia stem cells lie dormant. Standard cancer treatments are designed to seek out actively dividing cells. But in studies so far, DMAPT can kill both dormant cells and cells that are busy dividing, Guzman said
Rochester investigators looked at whether DMAPT could eliminate leukemia in donated human cells, and in mice and dogs. In all cases, DMAPT induced rapid death of AML stem and progenitor cells, without harming healthy blood cells.
DMAPT also has shown potential as a treatment for breast and prostate cancer, melanoma, and multiple myeloma, Guzman said, although those studies have only been conducted in cell cultures to date.
"Once we begin seeing evidence from the clinical trials, it will give us more insight into the pharmacological properties of DMAPT and it will be easier to figure out its potential for other cancers," Guzman said.
In addition to the studies of DMAPT, Guzman and Jordan also reported in the same issue of Blood on another new type of leukemia drug known as TDZD-8. Although this agent is at a much earlier stage of development, it also shows the ability to kill leukemia stem cells and may some day lead to better forms of treatment.
University of Rochester Medical Center
Leukemia News and Current Leukemia Events RSSMcGill researchers overcome chemotherapy resistance in the lab
Researchers from McGill University's Faculty of Medicine have discovered a compound that reduces resistance to chemotherapy agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI).
Crucial Factors in Lymphoma Development and Survival Discovered
Researchers at National Jewish Medical and Research Center have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer.
Leukemia drug could save lives of stroke patients
The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms.
Stroke study reveals key target for improving treatment and suggests that Gleevec may help
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
Math could help cure leukemia
When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer.
Combining math and medicine to treat leukemia
Researchers have produced a mathematical model that may lead to the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML).
Gene mutation improves leukemia drug's effect
Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.
Shilatifard Lab Identifies New Role for Factor Critical to Transcription
The Stowers Institute's Shilatifard Lab has identified a new role for the elongation factor ELL in gene transcription by RNA polymerase II (Pol II) - the enzyme that synthesizes messenger RNA to carry genetic information from DNA to the protein-synthesizing machinery of the cell.
Effective treatment for sickle cell underused by doctors
Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.
Ability to track stem cells in tumors could advance cancer treatments
Using noninvasive molecular imaging technology, a method has been developed to track the location and activity of mesenchymal stem cells (MSCs) in the tumors of living organisms.
More Leukemia News Articles
 | My Sister's Keeper: A Novel by Jodi Picoult |
 | Drums, Girls, And Dangerous Pie by Jordan Sonnenblick |
 | It's Only Temporary: The Good News and the Bad News of Being Alive by Evan Handler |
 | Sadako and the Thousand Paper Cranes (PMC) (Puffin Modern Classics) by Eleanor Coerr |
 | The Rainmaker by John Grisham |
 | Gideon's Gift (The Red Gloves Collection #1) by Karen Kingsbury |
 | The Breuss Cancer Cure: Advice for the Prevention and Natural Treatment of Cancer, Leukemia and Other Seemingly Incurable Diseases by Rudolf Breuss |
 | One Thousand Paper Cranes: The Story of Sadako and the Children's Peace Statue by Takayuki Ishii |
 | Time on Fire: My Comedy of Terrors by Evan Handler |
 | Childhood Leukemia: A Guide for Families, Friends and Caregivers (3rd Edition) by Nancy Keene |
| © 2008 BrightSurf.com |